Intellia Secures $605M Cash Runway; HAELO Phase 3 Data Due Mid-2026
Intellia ended 2025 with $605 million cash funding operations into H2 2027 and completed enrollment of its HAELO Phase 3 lonvo-z trial, with topline data due mid-2026 and BLA slated for late 2026. It is reactivating MAGNITUDE-2 nex-z and engaging FDA to lift the hold on its ATTR-CM trial.
1. Financial Position
Intellia closed 2025 with approximately $605 million in cash, cash equivalents and marketable securities, providing liquidity to fund operations into the second half of 2027. The strong balance sheet supports ongoing development and commercialization activities across its CRISPR-based therapeutic pipeline.
2. HAELO Phase 3 Trial
The company completed dosing and enrollment of 80 patients in the global HAELO Phase 3 trial of lonvo-z, with topline data expected by mid-2026. Intellia plans a Biologics License Application submission in the second half of 2026 and is building its commercial infrastructure in preparation for a potential first-half 2027 launch in hereditary angioedema.
3. MAGNITUDE Program Progress
Intellia is reactivating sites for MAGNITUDE-2, its Phase 3 trial of nex-z in ATTRv-PN, with enrollment completion targeted in the second half of 2026. Concurrently, the company is in active discussions with the FDA to resolve the clinical hold on the MAGNITUDE study in ATTR-CM, aiming to resume this trial promptly.